Loading…
Loading…
EQUITY / NASDAQ · XNCM
CervoMed Inc. Common Stock
01 / RESEARCH
8 financial reports are available for research.
Start research ↗2.93 USD · -1.3468%
Observed: Oct 1, 2026, 3:23 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
09/30/2026 · 2.97 USD · Volume 375,557
251 actual observations · Latest bar: 2026-09-30 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | Prior year | Change |
|---|---|---|---|
| Cash and cash equivalents | 22,462,577 USD | — | — |
| Net income | -6,571,656 USD | — | — |
| Operating profit | -6,678,551 USD | — | — |
| Revenue | 0 USD | — | — |
| Total assets | 25,992,471 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 2ConsolidatedUnits · USD | 2026 / Quarter 2ConsolidatedUnits · USD | 2026 / Quarter 2ConsolidatedUnits · USD | 2026 / Quarter 1ConsolidatedUnits · USD | 2025 / Quarter 2ConsolidatedUnits · USD | 2025 / Year endConsolidatedUnits · USD | 2025 / Quarter 3ConsolidatedUnits · USD | 2025 / Quarter 3ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 22,462,577 USD | — | — | 7,941,751 USD | 8,235,469 USD | 8,235,469 USD | 9,437,400 USD | — |
| Net incomeIncome statement | -6,571,656 USD | -14,535,814 USD | — | -7,964,158 USD | — | -26,966,367 USD | -7,726,639 USD | -18,879,077 USD |
| Operating profitIncome statement | -6,678,551 USD | -14,789,075 USD | — | -8,110,524 USD | — | -28,294,877 USD | -8,044,199 USD | -19,963,358 USD |
| RevenueIncome statement | 0 USD | 0 USD | — | 0 USD | — | 4,006,510 USD | 322,569 USD | 3,997,784 USD |
| Total assetsBalance sheet | 25,992,471 USD | — | — | 15,112,918 USD | 22,879,018 USD | 22,879,018 USD | 30,610,778 USD | — |
| Total equityBalance sheet | 22,960,297 USD | — | 10,615,715 USD | 10,615,715 USD | 18,222,901 USD | 18,222,901 USD | 26,011,464 USD | — |
| Total liabilitiesBalance sheet | 3,032,174 USD | — | — | 4,497,203 USD | 4,656,117 USD | 4,656,117 USD | 4,599,314 USD | — |
| Financing cash flowCash flow statement | — | 18,926,963 USD | — | 13,800 USD | — | 4,588,687 USD | — | 4,588,687 USD |
| Investing cash flowCash flow statement | — | 10,236,908 USD | — | 7,710,820 USD | — | 18,097,249 USD | — | 12,723,481 USD |
| Operating cash flowCash flow statement | — | -14,936,763 USD | — | -8,018,338 USD | — | -23,449,963 USD | — | -16,874,264 USD |
| Report source | Open report ↗ Published: 08/07/2026 | Open report ↗ Published: 08/07/2026 | Open report ↗ Published: 08/07/2026 | Open report ↗ Published: 05/15/2026 | Open report ↗ Published: 08/07/2026 | Open report ↗ Published: 03/13/2026 | Open report ↗ Published: 11/07/2025 | Open report ↗ Published: 11/07/2025 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.